Screener
Nektar Therapeutics NKTR Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | (10,861) | (10,460) |
| Non-cash interest expense on liabilities related to the sales of future royalties | 7,942 | 4,974 |
| Loss from equity method investment | 1,750 | 4,461 |
| Stock-based compensation | 3,355 | 3,898 |
| Depreciation and amortization | 151 | 426 |
| Amortization of premiums (discounts), net | (1,663) | (1,324) |
| Changes in operating assets and liabilities: | ||
| Operating leases, net | (2,409) | (1,813) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's stock-based comp?
- Nektar Therapeutics (NKTR) reported stock-based comp of $3.36M in Q1 2026.
- How has Nektar Therapeutics's stock-based comp changed year-over-year?
- Nektar Therapeutics's stock-based comp decreased by 13.9% year-over-year, from $3.9M to $3.36M.
- What is the long-term trend for Nektar Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Nektar Therapeutics's stock-based comp has grown at a -39.5% compound annual growth rate (CAGR), from $94.67M to $12.65M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Nektar Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude